QuidelOrtho Q3 revenue falls 11.6% to $619M
Outside China, Labs revenue grew 3.3% and Immunohematology revenue grew 1.7% year over year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
QuidelOrtho Corp (QDEL) reported third-quarter 2026 revenue of $618.9 million, down 11.6% from $699.9 million a year earlier. GAAP net loss was $53.8 million, compared with $733.0 million, while adjusted EBITDA was $148.0 million versus $177.1 million. Operating cash flow was $19.6 million, compared with $45.5 million used in the prior-year quarter; free cash flow was $0.3 million.
Point of Care revenue declined 27.3%. The company expects its restructuring program to deliver over $80 million in annual savings in 2027 and record approximately $30 million to $35 million in one-time charges in the fourth quarter of 2026. Updated 2026 guidance is $2.52 billion to $2.54 billion in revenue, $540 million to $545 million adjusted EBITDA, about 21% adjusted EBITDA margin and $0.65 to $0.70 adjusted diluted EPS. Effective November 9, 2026, the Board appointed Jonathan Siegrist, PhD, as Head of Point of Care Diagnostics and Bryan Hanson as Head of Core Diagnostics; Phil McLellan's employment as Chief Operations Officer will terminate.
2 points · 0 major0 major · 3 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointGAAP net loss narrowed to $53.8 million from $733.0 million.
- Moderate pointOperating cash flow was $19.6 million, versus $45.5 million used a year earlier.
Negative
- Moderate pointThird-quarter revenue fell 11.6% to $618.9 million.
- Moderate pointAdjusted EBITDA declined to $148.0 million from $177.1 million.
- Minor pointPoint of Care revenue fell 27.3% year over year.
Filing Explained
For the two business-head appointments effective
8-K Event Classification
3 items: 2.02, 5.02, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Third-quarter revenue: $618.9 million
GAAP net loss: $53.8 million
Adjusted EBITDA: $148.0 million
+5 more
8 metrics
Third-quarter revenue
$618.9 million
Three months ended September 27, 2026; $699.9 million in the prior-year quarter
GAAP net loss
$53.8 million
Three months ended September 27, 2026; $733.0 million in the prior-year quarter
Adjusted EBITDA
$148.0 million
Three months ended September 27, 2026; $177.1 million in the prior-year quarter
Operating cash flow
$19.6 million
Three months ended September 27, 2026; $45.5 million used in the prior-year quarter
Free cash flow
$0.3 million
Three months ended September 27, 2026; $(94.7) million in the prior-year quarter
Expected annual savings
Over $80 million
Expected in 2027 from the restructuring program
Expected restructuring charges
Approximately $30 million to $35 million
One-time charges expected in the fourth quarter of 2026
Full-year reported revenue guidance
$2.52 billion to $2.54 billion
Updated full-year 2026 guidance
Key Terms
adjusted EBITDA, constant currency, free cash flow, restricted stock units
4 terms
adjusted EBITDA financial
"adjusted EBITDA was $148 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
constant currency financial
"The term “constant currency” means we have translated local currency revenues"
Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.
free cash flow financial
"We define free cash flow as operating cash flows"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
restricted stock units financial
"2027 award in the form of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Earnings Snapshot
Total revenue: $618.9 million · Guidance included
Third quarter ended September 27, 2026
Total revenue
$618.9 million
-11.6% year over year
GAAP net loss
$53.8 million
Versus $733.0 million in the prior-year quarter
Adjusted EBITDA
$148.0 million
Versus $177.1 million in the prior-year quarter
Operating cash flow
$19.6 million
Versus $45.5 million used in the prior-year quarter
Free cash flow
$0.3 million
Versus $(94.7) million in the prior-year quarter
Guidance
Full-year 2026: reported revenue of $2.52 billion to $2.54 billion; adjusted EBITDA of $540 million to $545 million; adjusted EBITDA margin of ~21%; adjusted diluted EPS of $0.65 to $0.70.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were QDEL's third-quarter 2026 results?
Revenue was $618.9 million, down 11.6% from $699.9 million. GAAP net loss was $53.8 million, compared with $733.0 million; adjusted EBITDA was $148.0 million, versus $177.1 million. Operating cash flow was $19.6 million, compared with $45.5 million used in the prior-year quarter.
How much does QuidelOrtho expect its restructuring program to save?
QuidelOrtho expects over $80 million in annual savings in 2027 and approximately $30 million to $35 million in one-time restructuring charges in the fourth quarter of 2026. The program organizes operations around Core Diagnostics and Point of Care Diagnostics.
What is QDEL's updated 2026 financial guidance?
Updated full-year guidance lists reported revenue of $2.52 billion to $2.54 billion, adjusted EBITDA of $540 million to $545 million, adjusted EBITDA margin of ~21%, and adjusted diluted EPS of $0.65 to $0.70.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 3, 2026
(Exact name of Registrant as specified in its Charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(858 ) 552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release (the “Press Release”) announcing the financial results for its third quarter ended September 27, 2026, and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 3, 2026 to discuss such results. A copy of the Press Release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As reported in the Press Release, QuidelOrtho has initiated a cost transformation and enterprise restructuring program (the “Restructuring Plan”) designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. In connection with the Restructuring Plan, effective November 9, 2026 (the “Effective Date”), the QuidelOrtho Board of Directors (the “Board”) has appointed Jonathan Siegrist, PhD to serve in the newly created role of Head of Point of Care Diagnostics and Bryan Hanson to serve in the newly created role of Head of Core Diagnostics. Prior to their appointment to such roles, Dr. Siegrist served as QuidelOrtho’s Executive Vice President of Research & Development & Chief Technology Officer, and Mr. Hanson served as QuidelOrtho’s Executive Vice President, Global Portfolio Management and Marketing.
In connection with the appointment of Dr. Siegrist and Mr. Hanson to such new roles, QuidelOrtho entered into new employment offer letters with each of Dr. Siegrist and Mr. Hanson that provide for (i) an annual base salary of $650,000 and (ii) an annual target cash bonus opportunity of 100% of base salary. Each of Dr. Siegrist and Mr. Hanson will also receive a cash retention bonus in the amount of $650,000 that vests in full and is payable 12-months after the Effective Date. The employment offer letters also provide for future equity award grants, including a 2027 award in the form of restricted stock units with a grant date value of $2,000,000, which is subject to vesting in equal annual installments over a three-year period, and a 2028 award with a grant date value of $2,000,000, with the form and type of award to be determined at a later date. Each of Dr. Siegrist and Mr. Hanson will also be eligible for an annual executive physical, employer sponsored life insurance, and health, welfare and other benefits afforded to other QuidelOrtho executive officers. In addition, they will receive severance and change in control protection consistent with other arrangements with executive officers pursuant to a Severance and Change in Control Agreement (the “Severance and CIC Agreement”), substantially in the form as filed as Exhibit 10.15 to the QuidelOrtho Annual Report on Form 10-K for the year ended December 28, 2025, filed on February 19, 2026. The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the employment offer letters with each of Dr. Siegrist and Mr. Hanson, copies of which will be filed as exhibits to QuidelOrtho’s Annual Report on Form 10-K for the 2026 fiscal year.
Pursuant to the Restructuring Plan, the Board also approved the elimination of the role of Chief Operations Officer. Effective the Effective Date, the employment of Phil McLellan as QuidelOrtho’s Chief Operations Officer will terminate, following which Mr. McLellan shall cease to be an executive officer of QuidelOrtho under the Exchange Act. Mr. McLellan will be eligible for severance and other benefits in accordance with the terms of his Severance and Change in Control Agreement.
Item 9.01 Financial Statements and Exhibits.
| (d) Exhibits. | ||||||||||||||
| The following exhibit is furnished with this Form 8-K: | ||||||||||||||
| Exhibit Number | Description of Exhibit | |||||||||||||
| 99.1 | Press release, dated November 3, 2026, reporting QuidelOrtho Corporation's financial results for its third quarter ended September 27, 2026. | |||||||||||||
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document. | |||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 3, 2026
| QUIDELORTHO CORPORATION | ||||||||
| By: | /s/ MICAH YOUNG | |||||||
| Name: | Micah Young | |||||||
| Its: | Chief Financial Officer | |||||||
Exhibit 99.1
QuidelOrtho Reports Third Quarter 2026 Financial Results
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―
― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―
― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―
November 3, 2026
SAN DIEGO, CA November 3, 2026 — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026.
Key Third Quarter 2026 Results:
(all comparisons are to the prior year period)
•Total revenue was $619 million, a decrease of 12% both as reported and in constant currency. Excluding respiratory, China, and the U.S. Donor Screening business, total revenue grew 2% as reported and 3% in constant currency, reflecting the underlying strength of the business.
◦Labs revenue of $353 million declined 6% both as reported and in constant currency, primarily due to lower sales in China related to recently announced changes to In Vitro Diagnostics pricing. Outside China, Labs revenue grew 3% as reported and 4% in constant currency, driven by continued strength across the business.
◦Immunohematology revenue of $142 million was flat as reported and increased 1% in constant currency. Outside China, Immunohematology revenue grew 2% as reported and 3% in constant currency.
◦Point of Care revenue of $120 million declined 27% both as reported and in constant currency due to a softer respiratory season.
•GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million.
•GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted EBITDA margin was 23.9%.
•GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31.
•Operating cash flow was $20 million; free cash flow was $0.3 million.
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. “While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program. This program is designed to improve profitability and cash flow while evolving our operating model around the distinct needs of our customers and markets. We believe these actions will help mitigate near-term headwinds and position the Company for sustainable long-term growth.”
Cost Transformation and Restructuring Program
The Company has initiated a new cost transformation and enterprise restructuring program designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. The Company expects the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.
Full-year 2026 Financial Guidance
Based on its current business outlook, the Company is updating its full-year financial guidance below:
| Full-year 2026 Financial Guidance | As of 11/3/2026 | As of 8/6/2026 | ||||||
| Total revenues (reported) | $2.52 - $2.54 billion | $2.52 - $2.60 billion | ||||||
| Adjusted EBITDA | $540 - $545 million | $540 - $560 million | ||||||
| Adjusted EBITDA margin | ~21% | 21% - 22% | ||||||
| Adjusted diluted EPS | $0.65 - $0.70 | $0.65 - $0.90 | ||||||
Please see page 8 of the Third Quarter 2026 Financial Results presentation on the “Investor Relations” page of the Company’s website for the full list of assumptions on which the Company’s current 2026 financial guidance is based.
A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."
Conference Call Information
QuidelOrtho will hold a conference call and webcast today beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the live webcast on the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/events-and-presentations. A replay of the webcast will be available shortly after the event on the Company’s website.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, including the expected results and anticipated benefits of the cost transformation and enterprise restructuring program and the timing and amount of related charges, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “could,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue,” “aim,” “strive,” “seek” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual
results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho’s non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Non-GAAP Financial Measures
This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to “constant currency total revenue changes,” “constant currency total revenue changes, excluding respiratory, China and the U.S. Donor Screening business,” “constant currency Labs revenue changes,” “constant currency Labs revenue changes, excluding China,” “constant currency Immunohematology revenue changes,” “constant currency Immunohematology revenue changes, excluding China,” “constant currency Point of Care revenue changes,” “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted diluted EPS,” “free cash flow” and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.
Investor Contact:
Sanjeev Sharma
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
media@QuidelOrtho.com
QuidelOrtho
Consolidated Statements of Loss
(Unaudited)
(In millions, except per share data)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | September 27, 2026 | September 28, 2025 | ||||||||||||||||||||
| Total revenues | $ | 618.9 | $ | 699.9 | $ | 1,869.6 | $ | 2,006.6 | |||||||||||||||
| Cost of sales, excluding amortization of intangibles | 329.3 | 364.3 | 1,043.3 | 1,052.8 | |||||||||||||||||||
| Selling, marketing and administrative | 182.7 | 186.9 | 571.7 | 551.9 | |||||||||||||||||||
| Research and development | 42.5 | 41.5 | 136.1 | 140.4 | |||||||||||||||||||
| Amortization of intangible assets | 50.8 | 47.7 | 146.6 | 143.6 | |||||||||||||||||||
| Restructuring, integration and other charges | 7.1 | 39.6 | 18.0 | 234.6 | |||||||||||||||||||
| Goodwill impairment charge | — | 700.7 | — | 700.7 | |||||||||||||||||||
| Asset impairment charge | 12.5 | 9.7 | 12.5 | 9.7 | |||||||||||||||||||
| Other operating expenses | 1.5 | 14.3 | 2.5 | 25.8 | |||||||||||||||||||
| Operating loss | (7.5) | (704.8) | (61.1) | (852.9) | |||||||||||||||||||
| Interest expense, net | 55.4 | 46.1 | 161.2 | 126.6 | |||||||||||||||||||
| Loss on extinguishment of debt | — | 5.1 | — | 5.1 | |||||||||||||||||||
| Other expense, net | — | 0.9 | 1.3 | 10.7 | |||||||||||||||||||
| Loss before income taxes | (62.9) | (756.9) | (223.6) | (995.3) | |||||||||||||||||||
| (Benefit from) provision for income taxes | (9.1) | (23.9) | 14.9 | 5.8 | |||||||||||||||||||
| Net loss | $ | (53.8) | $ | (733.0) | $ | (238.5) | $ | (1,001.1) | |||||||||||||||
| Basic loss per share | $ | (0.78) | $ | (10.78) | $ | (3.49) | $ | (14.79) | |||||||||||||||
| Diluted loss per share | $ | (0.78) | $ | (10.78) | $ | (3.49) | $ | (14.79) | |||||||||||||||
| Weighted-average shares outstanding - basic | 68.7 | 68.0 | 68.4 | 67.7 | |||||||||||||||||||
| Weighted-average shares outstanding - diluted | 68.7 | 68.0 | 68.4 | 67.7 | |||||||||||||||||||
QuidelOrtho
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions)
| September 27, 2026 | December 28, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 166.4 | $ | 169.8 | |||||||
| Accounts receivable, net | 375.5 | 417.0 | |||||||||
| Inventories | 642.7 | 577.6 | |||||||||
| Prepaid expenses and other current assets | 241.5 | 250.5 | |||||||||
| Assets held for sale | 19.9 | 32.4 | |||||||||
| Total current assets | 1,446.0 | 1,447.3 | |||||||||
| Property, plant and equipment, net | 1,323.6 | 1,358.3 | |||||||||
| Right-of-use assets | 151.0 | 155.5 | |||||||||
| Intangible assets, net | 2,628.3 | 2,563.8 | |||||||||
| Other assets | 232.4 | 244.4 | |||||||||
| Total assets | $ | 5,781.3 | $ | 5,769.3 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 253.3 | $ | 279.4 | |||||||
| Accrued payroll and related expenses | 76.4 | 120.3 | |||||||||
| Income tax payable | 3.3 | 11.5 | |||||||||
| Current portion of borrowings | 424.4 | 178.3 | |||||||||
| Other current liabilities | 309.7 | 376.6 | |||||||||
| Total current liabilities | 1,067.1 | 966.1 | |||||||||
| Operating lease liabilities | 146.9 | 154.4 | |||||||||
| Long-term borrowings | 2,512.9 | 2,471.9 | |||||||||
| Deferred tax liabilities | 121.5 | 90.0 | |||||||||
| Other liabilities | 141.6 | 166.4 | |||||||||
| Total liabilities | 3,990.0 | 3,848.8 | |||||||||
| Total stockholders’ equity | 1,791.3 | 1,920.5 | |||||||||
| Total liabilities and stockholders’ equity | $ | 5,781.3 | $ | 5,769.3 | |||||||
QuidelOrtho
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | September 27, 2026 | September 28, 2025 | ||||||||||||||||||||
| Cash provided by (used for) operating activities | $ | 19.6 | $ | (45.5) | $ | (124.0) | $ | (26.7) | |||||||||||||||
| Cash used for investing activities | (20.9) | (53.9) | (162.2) | (143.1) | |||||||||||||||||||
| Cash provided by financing activities | 44.1 | 46.0 | 282.3 | 166.9 | |||||||||||||||||||
| Effect of exchange rates on cash | 0.2 | (0.2) | 0.5 | 2.5 | |||||||||||||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 43.0 | (53.6) | (3.4) | (0.4) | |||||||||||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 123.4 | 151.7 | 169.8 | 98.5 | |||||||||||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 166.4 | $ | 98.1 | $ | 166.4 | $ | 98.1 | |||||||||||||||
Free Cash Flow (a): | |||||||||||||||||||||||
| Cash provided by (used for) operating activities | $ | 19.6 | $ | (45.5) | $ | (124.0) | $ | (26.7) | |||||||||||||||
| Less: Acquisitions of property, plant, equipment, investments and intangibles (capital expenditures) | (20.4) | (49.2) | (80.5) | (143.7) | |||||||||||||||||||
| Plus: Proceeds from sale of property, plant and equipment (capital disposals) | 1.1 | — | 1.7 | 0.8 | |||||||||||||||||||
| Free Cash Flow (non-GAAP) | $ | 0.3 | $ | (94.7) | $ | (202.8) | $ | (169.6) | |||||||||||||||
(a) We define free cash flow as operating cash flows, less payments for acquisitions of property, plant, equipment, investments and intangibles (“capital expenditures”) plus the proceeds from sale of property, plant and equipment (“capital disposals”).
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Net Income
(In millions, except per share data; unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
| September 27, 2026 | Diluted EPS | September 28, 2025 | Diluted EPS | September 27, 2026 | Diluted EPS | September 28, 2025 | Diluted EPS | ||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (53.8) | $ | (0.78) | $ | (733.0) | $ | (10.78) | $ | (238.5) | $ | (3.49) | $ | (1,001.1) | $ | (14.79) | |||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of intangibles | 50.8 | 47.7 | 146.6 | 143.6 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring, integration and other charges | 7.1 | 39.6 | 18.0 | 234.6 | |||||||||||||||||||||||||||||||||||||||||||
| Goodwill impairment charge | — | 700.7 | — | 700.7 | |||||||||||||||||||||||||||||||||||||||||||
| Asset impairment charge | 12.5 | 9.7 | 12.5 | 9.7 | |||||||||||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | — | 5.1 | — | 5.1 | |||||||||||||||||||||||||||||||||||||||||||
| Legal accrual | — | 9.4 | — | 9.4 | |||||||||||||||||||||||||||||||||||||||||||
| Amortization of deferred cloud computing implementation costs | 9.1 | 7.9 | 26.3 | 19.0 | |||||||||||||||||||||||||||||||||||||||||||
| Employee compensation charges | 3.7 | — | 13.7 | — | |||||||||||||||||||||||||||||||||||||||||||
| Tax indemnification expense | — | — | 3.3 | — | |||||||||||||||||||||||||||||||||||||||||||
| Incremental depreciation on PP&E fair value adjustment | 3.4 | 5.1 | 9.9 | 15.7 | |||||||||||||||||||||||||||||||||||||||||||
| Accelerated depreciation | 2.0 | 1.5 | 6.1 | 2.5 | |||||||||||||||||||||||||||||||||||||||||||
| EU medical device regulation transition costs | 0.2 | 0.2 | 1.6 | 0.5 | |||||||||||||||||||||||||||||||||||||||||||
| Loss (gain) on investments | — | 0.6 | 9.0 | (0.7) | |||||||||||||||||||||||||||||||||||||||||||
| Credit Agreement amendment fees | 0.5 | — | 0.5 | — | |||||||||||||||||||||||||||||||||||||||||||
| Other adjustments | 2.8 | 2.6 | 14.3 | 4.6 | |||||||||||||||||||||||||||||||||||||||||||
| Income tax impact of adjustments | (17.1) | (42.4) | 4.7 | (30.8) | |||||||||||||||||||||||||||||||||||||||||||
| Adjusted net income | $ | 21.2 | $ | 0.31 | $ | 54.7 | $ | 0.80 | $ | 28.0 | $ | 0.41 | $ | 112.8 | $ | 1.66 | |||||||||||||||||||||||||||||||
| Weighted-average shares outstanding - diluted | 69.1 | 68.1 | 68.7 | 68.0 | |||||||||||||||||||||||||||||||||||||||||||
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA
(In millions, unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | September 27, 2026 | September 28, 2025 | ||||||||||||||||||||
| Net loss | $ | (53.8) | $ | (733.0) | $ | (238.5) | $ | (1,001.1) | |||||||||||||||
| Depreciation and amortization | 119.6 | 112.1 | 349.2 | 329.5 | |||||||||||||||||||
| Interest expense, net | 55.4 | 46.1 | 161.2 | 126.6 | |||||||||||||||||||
| (Benefit from) provision for income taxes | (9.1) | (23.9) | 14.9 | 5.8 | |||||||||||||||||||
| Restructuring, integration and other charges | 7.1 | 39.6 | 18.0 | 234.6 | |||||||||||||||||||
| Goodwill impairment charge | — | 700.7 | — | 700.7 | |||||||||||||||||||
| Asset impairment charge | 12.5 | 9.7 | 12.5 | 9.7 | |||||||||||||||||||
| Loss on extinguishment of debt | — | 5.1 | — | 5.1 | |||||||||||||||||||
| Legal accrual | — | 9.4 | — | 9.4 | |||||||||||||||||||
| Amortization of deferred cloud computing implementation costs | 9.1 | 7.9 | 26.3 | 19.0 | |||||||||||||||||||
| Employee compensation charges | 3.7 | — | 13.7 | — | |||||||||||||||||||
| Tax indemnification expense | — | — | 3.3 | — | |||||||||||||||||||
| EU medical device regulation transition costs | 0.2 | 0.2 | 1.6 | 0.5 | |||||||||||||||||||
| Loss (gain) on investments | — | 0.6 | 9.0 | (0.7) | |||||||||||||||||||
| Credit Agreement amendment fees | 0.5 | — | 0.5 | — | |||||||||||||||||||
| Other adjustments | 2.8 | 2.6 | 14.3 | 4.6 | |||||||||||||||||||
| Adjusted EBITDA | $ | 148.0 | $ | 177.1 | $ | 386.0 | $ | 443.7 | |||||||||||||||
| Total revenues | $ | 618.9 | $ | 699.9 | $ | 1,869.6 | $ | 2,006.6 | |||||||||||||||
| Adjusted EBITDA margin | 23.9 | % | 25.3 | % | 20.6 | % | 22.1 | % | |||||||||||||||
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Revenues
(In millions, unaudited)
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Labs | $ | 353.2 | $ | 373.8 | (5.5) | % | 0.4 | % | (5.9) | % | |||||||||||||||||||
| Immunohematology | 142.0 | 142.0 | — | % | (0.9) | % | 0.9 | % | |||||||||||||||||||||
| Donor Screening | 1.7 | 14.7 | (88.4) | % | — | % | (88.4) | % | |||||||||||||||||||||
| Point of Care | 119.6 | 164.6 | (27.3) | % | (0.1) | % | (27.2) | % | |||||||||||||||||||||
| Molecular Diagnostics | 2.4 | 4.8 | (50.0) | % | (0.7) | % | (49.3) | % | |||||||||||||||||||||
| Total revenues | $ | 618.9 | $ | 699.9 | (11.6) | % | — | % | (11.6) | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Total revenues | $ | 618.9 | $ | 699.9 | (11.6) | % | — | % | (11.6) | % | |||||||||||||||||||
| Respiratory | 68.8 | 112.3 | (38.7) | % | — | % | (38.7) | % | |||||||||||||||||||||
| China excluding respiratory | 48.4 | 84.4 | (42.7) | % | 3.2 | % | (45.9) | % | |||||||||||||||||||||
| U.S. Donor Screening | 0.5 | 13.1 | (96.0) | % | — | % | (96.0) | % | |||||||||||||||||||||
| Total revenues excluding respiratory, China, and U.S. Donor Screening | $ | 501.2 | $ | 490.1 | 2.3 | % | (0.7) | % | 3.0 | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Labs | $ | 353.2 | $ | 373.8 | (5.5) | % | 0.4 | % | (5.9) | % | |||||||||||||||||||
| China Labs | 36.9 | 67.7 | (45.5) | % | 3.2 | % | (48.7) | % | |||||||||||||||||||||
| Total Labs revenues excluding China | $ | 316.3 | $ | 306.1 | 3.3 | % | (0.5) | % | 3.8 | % | |||||||||||||||||||
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.
| Three Months Ended | |||||||||||||||||||||||||||||
| September 27, 2026 | September 28, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Immunohematology | $ | 142.0 | $ | 142.0 | — | % | (0.9) | % | 0.9 | % | |||||||||||||||||||
| China Immunohematology | 8.0 | 10.2 | (21.6) | % | 4.1 | % | (25.7) | % | |||||||||||||||||||||
| Total Immunohematology revenues excluding China | $ | 134.0 | $ | 131.8 | 1.7 | % | (1.3) | % | 3.0 | % | |||||||||||||||||||
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.